Home › Encyclopedia › Thymopentin: Research Status, Trials, and Identity
Research / Unapproved

Thymopentin: Research Status, Trials, and Identity

Molecular formulaC30H49N9O9
Molecular weight679.8 g/mol
Registered trials12
PubChem CID451417

Thymopentin is a synthetic peptide studied in clinical research settings but it does not have an approved drug label. Anyone researching this compound should understand that its regulatory status is investigational, not approved for medical use.

What thymopentin is

Thymopentin is a peptide with the molecular formula C30H49N9O9 and a molecular weight of about 679.8 (PubChem CID 451417). No FDA label, indication, mechanism description, or approved brand name exists for this compound in the data reviewed. It has not been evaluated or authorized by regulators for any medical condition.

Trial footprint

Thymopentin has been the subject of 12 registered clinical trials. Among the sampled studies, one completed trial examined its effects on HIV infectivity of blood cells and semen in HIV-infected patients, and two other completed, double-blind studies looked at its effects in patients with HIV-1 infection. These trials are historical registry entries and do not by themselves establish that the compound is safe or effective for any use.

FAQ

Is thymopentin FDA-approved?
No. Thymopentin does not have an FDA-approved label, brand name, or approved indication based on the data reviewed. It remains an unapproved research compound.
What is thymopentin made of?
Thymopentin is a synthetic peptide with the molecular formula C30H49N9O9 and a molecular weight of approximately 679.8. It is cataloged in PubChem under CID 451417.
What has thymopentin been studied for?
Registered trials have examined thymopentin in the context of HIV-1 infection, including its effects on blood cell and semen infectivity in HIV-infected patients. A total of 12 clinical trials have been registered for this compound.
Are the thymopentin trials still active?
The sampled trials, including studies on HIV infectivity and double-blind HIV-1 studies, are listed as completed. Completion of a trial does not indicate proven safety or effectiveness.
Can thymopentin be used as a treatment today?
No. Because thymopentin lacks an approved label, it is not authorized for treating any condition and any use falls outside approved medical practice.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 451417 ClinicalTrials.gov

Updated 2026-09-19